United Homes Group stock plunges after Nikki Haley, directors resign
RICHMOND - Pharmaceutical company Indivior PLC (NASDAQ:INDV), currently valued at $3.01 billion and trading near its 52-week high of $25.10, announced Wednesday its intention to change its corporate domicile from the United Kingdom to the United States, establishing a new U.S. parent company called Indivior Pharmaceuticals, Inc.
The proposed restructuring follows Indivior’s U.S. listing on Nasdaq in June 2023 and subsequent cancellation of its London Stock Exchange listing in July 2025. The company’s board is recommending the change to maximize benefits of its U.S. stock listing, including expanding its U.S. capital markets presence, increasing potential U.S. equity indexation, and simplifying corporate governance. The move comes amid strong market performance, with the stock delivering a 94% return year-to-date. According to InvestingPro, three analysts have recently revised their earnings estimates upward for the upcoming period.
The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement, requiring shareholder approval. Under the plan, Indivior PLC will become a direct wholly owned subsidiary of the new Delaware-incorporated entity. Shareholders will receive one new share in Indivior Pharmaceuticals for each Indivior PLC share they currently hold.
No additional equity will be raised as part of the transaction, and the company’s shares will continue trading on Nasdaq under the same "INDV" symbol.
The timeline for the restructuring includes issuing a shareholder circular in mid-November 2025, holding an extraordinary general meeting in early December 2025, and completing the transition by late January 2026. InvestingPro data shows the company maintains a "GREAT" financial health score of 3.29, suggesting strong positioning for this corporate transition. Subscribers can access 11 additional exclusive ProTips and comprehensive financial metrics for deeper analysis.
The scheme requires approval by a majority of Indivior shareholders representing 75% in value of the shares voted at the meeting.
Indivior, which focuses on developing treatments for opioid use disorder, indicated in its press release statement that the move would further position it as a U.S.-based treatment innovator, enabling closer collaboration with public health leaders. The company operates with an impressive 84% gross profit margin and maintains moderate debt levels, according to InvestingPro’s detailed financial analysis.
In other recent news, Indivior PLC reported a significant earnings beat for the second quarter of 2025, with earnings per share of $0.51, surpassing the forecast of $0.24 by 112.5%. The company’s revenue reached $302 million, exceeding expectations by 24.96%. This strong financial performance was accompanied by the announcement of restructuring charges estimated between $39 million and $50 million, as part of its "Action Agenda" to streamline operations. Indivior’s plan includes organizational changes and exploring strategic options for its Opvee product and ex-U.S. business operations.
Craig-Hallum responded to these developments by raising its price target for Indivior’s stock from $27 to $34 while maintaining a Buy rating. Piper Sandler also reiterated its Overweight rating with a $27 price target, reflecting continued confidence in the company’s strategic initiatives. Additionally, Indivior updated its employment agreements with CFO Ryan Preblick, aligning them with the company’s current forms for U.S.-based executives, without altering his compensation. These developments highlight Indivior’s ongoing efforts to enhance operational efficiency and focus on the U.S. market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.